Global Pulmonary Drugs Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
LPI (LP Information)' newest research report, the “Pulmonary Drugs Industry Forecast” looks at past sales and reviews total world Pulmonary Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Pulmonary Drugs sales for 2023 through 2029. With Pulmonary Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Drugs industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pulmonary Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Drugs.
The global Pulmonary Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Pulmonary Drugs market?
What factors are driving Pulmonary Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Drugs market opportunities vary by end market size?
How does Pulmonary Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
LPI (LP Information)' newest research report, the “Pulmonary Drugs Industry Forecast” looks at past sales and reviews total world Pulmonary Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Pulmonary Drugs sales for 2023 through 2029. With Pulmonary Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Pulmonary Drugs industry.
This Insight Report provides a comprehensive analysis of the global Pulmonary Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Pulmonary Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Pulmonary Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Pulmonary Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Pulmonary Drugs.
The global Pulmonary Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives.
This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Others
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZeneca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi Farmaceutici S.p.A
- Zambon Company S.p.A
- Alaxia SAS
- Merck Sharp & Dohme Limited
What is the 10-year outlook for the global Pulmonary Drugs market?
What factors are driving Pulmonary Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Pulmonary Drugs market opportunities vary by end market size?
How does Pulmonary Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pulmonary Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Pulmonary Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Pulmonary Drugs by Country/Region, 2018, 2022 & 2029
2.2 Pulmonary Drugs Segment by Type
2.2.1 Inhaled Corticosteroids
2.2.2 Long Acting Beta-2 Agonists
2.2.3 Antihistamines
2.2.4 Vasodilators
2.2.5 Others
2.3 Pulmonary Drugs Sales by Type
2.3.1 Global Pulmonary Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Pulmonary Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Pulmonary Drugs Sale Price by Type (2018-2023)
2.4 Pulmonary Drugs Segment by Application
2.4.1 Asthma & COPD
2.4.2 Allergic Rhinitis
2.4.3 Pulmonary Arterial Hypertension
2.4.4 Cystic Fibrosis
2.4.5 Others
2.5 Pulmonary Drugs Sales by Application
2.5.1 Global Pulmonary Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Pulmonary Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Pulmonary Drugs Sale Price by Application (2018-2023)
3 GLOBAL PULMONARY DRUGS BY COMPANY
3.1 Global Pulmonary Drugs Breakdown Data by Company
3.1.1 Global Pulmonary Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Pulmonary Drugs Sales Market Share by Company (2018-2023)
3.2 Global Pulmonary Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Pulmonary Drugs Revenue by Company (2018-2023)
3.2.2 Global Pulmonary Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Pulmonary Drugs Sale Price by Company
3.4 Key Manufacturers Pulmonary Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Drugs Product Location Distribution
3.4.2 Players Pulmonary Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PULMONARY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Pulmonary Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Pulmonary Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Pulmonary Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Pulmonary Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Pulmonary Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Pulmonary Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Pulmonary Drugs Sales Growth
4.4 APAC Pulmonary Drugs Sales Growth
4.5 Europe Pulmonary Drugs Sales Growth
4.6 Middle East & Africa Pulmonary Drugs Sales Growth
5 AMERICAS
5.1 Americas Pulmonary Drugs Sales by Country
5.1.1 Americas Pulmonary Drugs Sales by Country (2018-2023)
5.1.2 Americas Pulmonary Drugs Revenue by Country (2018-2023)
5.2 Americas Pulmonary Drugs Sales by Type
5.3 Americas Pulmonary Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Drugs Sales by Region
6.1.1 APAC Pulmonary Drugs Sales by Region (2018-2023)
6.1.2 APAC Pulmonary Drugs Revenue by Region (2018-2023)
6.2 APAC Pulmonary Drugs Sales by Type
6.3 APAC Pulmonary Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pulmonary Drugs by Country
7.1.1 Europe Pulmonary Drugs Sales by Country (2018-2023)
7.1.2 Europe Pulmonary Drugs Revenue by Country (2018-2023)
7.2 Europe Pulmonary Drugs Sales by Type
7.3 Europe Pulmonary Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pulmonary Drugs by Country
8.1.1 Middle East & Africa Pulmonary Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Pulmonary Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Pulmonary Drugs Sales by Type
8.3 Middle East & Africa Pulmonary Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Drugs
10.3 Manufacturing Process Analysis of Pulmonary Drugs
10.4 Industry Chain Structure of Pulmonary Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Drugs Distributors
11.3 Pulmonary Drugs Customer
12 WORLD FORECAST REVIEW FOR PULMONARY DRUGS BY GEOGRAPHIC REGION
12.1 Global Pulmonary Drugs Market Size Forecast by Region
12.1.1 Global Pulmonary Drugs Forecast by Region (2024-2029)
12.1.2 Global Pulmonary Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Pulmonary Drugs Forecast by Type
12.7 Global Pulmonary Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi SA
13.1.1 Sanofi SA Company Information
13.1.2 Sanofi SA Pulmonary Drugs Product Portfolios and Specifications
13.1.3 Sanofi SA Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi SA Main Business Overview
13.1.5 Sanofi SA Latest Developments
13.2 Meda Pharmaceuticals
13.2.1 Meda Pharmaceuticals Company Information
13.2.2 Meda Pharmaceuticals Pulmonary Drugs Product Portfolios and Specifications
13.2.3 Meda Pharmaceuticals Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Meda Pharmaceuticals Main Business Overview
13.2.5 Meda Pharmaceuticals Latest Developments
13.3 Circassia Pharmaceuticals Plc.
13.3.1 Circassia Pharmaceuticals Plc. Company Information
13.3.2 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
13.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Circassia Pharmaceuticals Plc. Main Business Overview
13.3.5 Circassia Pharmaceuticals Plc. Latest Developments
13.4 AstraZeneca Plc.
13.4.1 AstraZeneca Plc. Company Information
13.4.2 AstraZeneca Plc. Pulmonary Drugs Product Portfolios and Specifications
13.4.3 AstraZeneca Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 AstraZeneca Plc. Main Business Overview
13.4.5 AstraZeneca Plc. Latest Developments
13.5 GlaxoSmithKline Plc.
13.5.1 GlaxoSmithKline Plc. Company Information
13.5.2 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolios and Specifications
13.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 GlaxoSmithKline Plc. Main Business Overview
13.5.5 GlaxoSmithKline Plc. Latest Developments
13.6 Mallinckrodt Pharmaceuticals Plc.
13.6.1 Mallinckrodt Pharmaceuticals Plc. Company Information
13.6.2 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
13.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Mallinckrodt Pharmaceuticals Plc. Main Business Overview
13.6.5 Mallinckrodt Pharmaceuticals Plc. Latest Developments
13.7 Cheisi Farmaceutici S.p.A
13.7.1 Cheisi Farmaceutici S.p.A Company Information
13.7.2 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolios and Specifications
13.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Cheisi Farmaceutici S.p.A Main Business Overview
13.7.5 Cheisi Farmaceutici S.p.A Latest Developments
13.8 Zambon Company S.p.A
13.8.1 Zambon Company S.p.A Company Information
13.8.2 Zambon Company S.p.A Pulmonary Drugs Product Portfolios and Specifications
13.8.3 Zambon Company S.p.A Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Zambon Company S.p.A Main Business Overview
13.8.5 Zambon Company S.p.A Latest Developments
13.9 Alaxia SAS
13.9.1 Alaxia SAS Company Information
13.9.2 Alaxia SAS Pulmonary Drugs Product Portfolios and Specifications
13.9.3 Alaxia SAS Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Alaxia SAS Main Business Overview
13.9.5 Alaxia SAS Latest Developments
13.10 Merck Sharp & Dohme Limited
13.10.1 Merck Sharp & Dohme Limited Company Information
13.10.2 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolios and Specifications
13.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck Sharp & Dohme Limited Main Business Overview
13.10.5 Merck Sharp & Dohme Limited Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Pulmonary Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Pulmonary Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Pulmonary Drugs by Country/Region, 2018, 2022 & 2029
2.2 Pulmonary Drugs Segment by Type
2.2.1 Inhaled Corticosteroids
2.2.2 Long Acting Beta-2 Agonists
2.2.3 Antihistamines
2.2.4 Vasodilators
2.2.5 Others
2.3 Pulmonary Drugs Sales by Type
2.3.1 Global Pulmonary Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Pulmonary Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Pulmonary Drugs Sale Price by Type (2018-2023)
2.4 Pulmonary Drugs Segment by Application
2.4.1 Asthma & COPD
2.4.2 Allergic Rhinitis
2.4.3 Pulmonary Arterial Hypertension
2.4.4 Cystic Fibrosis
2.4.5 Others
2.5 Pulmonary Drugs Sales by Application
2.5.1 Global Pulmonary Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Pulmonary Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Pulmonary Drugs Sale Price by Application (2018-2023)
3 GLOBAL PULMONARY DRUGS BY COMPANY
3.1 Global Pulmonary Drugs Breakdown Data by Company
3.1.1 Global Pulmonary Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Pulmonary Drugs Sales Market Share by Company (2018-2023)
3.2 Global Pulmonary Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Pulmonary Drugs Revenue by Company (2018-2023)
3.2.2 Global Pulmonary Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Pulmonary Drugs Sale Price by Company
3.4 Key Manufacturers Pulmonary Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Pulmonary Drugs Product Location Distribution
3.4.2 Players Pulmonary Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR PULMONARY DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Pulmonary Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Pulmonary Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Pulmonary Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Pulmonary Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Pulmonary Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Pulmonary Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Pulmonary Drugs Sales Growth
4.4 APAC Pulmonary Drugs Sales Growth
4.5 Europe Pulmonary Drugs Sales Growth
4.6 Middle East & Africa Pulmonary Drugs Sales Growth
5 AMERICAS
5.1 Americas Pulmonary Drugs Sales by Country
5.1.1 Americas Pulmonary Drugs Sales by Country (2018-2023)
5.1.2 Americas Pulmonary Drugs Revenue by Country (2018-2023)
5.2 Americas Pulmonary Drugs Sales by Type
5.3 Americas Pulmonary Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Pulmonary Drugs Sales by Region
6.1.1 APAC Pulmonary Drugs Sales by Region (2018-2023)
6.1.2 APAC Pulmonary Drugs Revenue by Region (2018-2023)
6.2 APAC Pulmonary Drugs Sales by Type
6.3 APAC Pulmonary Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Pulmonary Drugs by Country
7.1.1 Europe Pulmonary Drugs Sales by Country (2018-2023)
7.1.2 Europe Pulmonary Drugs Revenue by Country (2018-2023)
7.2 Europe Pulmonary Drugs Sales by Type
7.3 Europe Pulmonary Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Pulmonary Drugs by Country
8.1.1 Middle East & Africa Pulmonary Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Pulmonary Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Pulmonary Drugs Sales by Type
8.3 Middle East & Africa Pulmonary Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Pulmonary Drugs
10.3 Manufacturing Process Analysis of Pulmonary Drugs
10.4 Industry Chain Structure of Pulmonary Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Pulmonary Drugs Distributors
11.3 Pulmonary Drugs Customer
12 WORLD FORECAST REVIEW FOR PULMONARY DRUGS BY GEOGRAPHIC REGION
12.1 Global Pulmonary Drugs Market Size Forecast by Region
12.1.1 Global Pulmonary Drugs Forecast by Region (2024-2029)
12.1.2 Global Pulmonary Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Pulmonary Drugs Forecast by Type
12.7 Global Pulmonary Drugs Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Sanofi SA
13.1.1 Sanofi SA Company Information
13.1.2 Sanofi SA Pulmonary Drugs Product Portfolios and Specifications
13.1.3 Sanofi SA Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi SA Main Business Overview
13.1.5 Sanofi SA Latest Developments
13.2 Meda Pharmaceuticals
13.2.1 Meda Pharmaceuticals Company Information
13.2.2 Meda Pharmaceuticals Pulmonary Drugs Product Portfolios and Specifications
13.2.3 Meda Pharmaceuticals Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Meda Pharmaceuticals Main Business Overview
13.2.5 Meda Pharmaceuticals Latest Developments
13.3 Circassia Pharmaceuticals Plc.
13.3.1 Circassia Pharmaceuticals Plc. Company Information
13.3.2 Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
13.3.3 Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Circassia Pharmaceuticals Plc. Main Business Overview
13.3.5 Circassia Pharmaceuticals Plc. Latest Developments
13.4 AstraZeneca Plc.
13.4.1 AstraZeneca Plc. Company Information
13.4.2 AstraZeneca Plc. Pulmonary Drugs Product Portfolios and Specifications
13.4.3 AstraZeneca Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 AstraZeneca Plc. Main Business Overview
13.4.5 AstraZeneca Plc. Latest Developments
13.5 GlaxoSmithKline Plc.
13.5.1 GlaxoSmithKline Plc. Company Information
13.5.2 GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolios and Specifications
13.5.3 GlaxoSmithKline Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 GlaxoSmithKline Plc. Main Business Overview
13.5.5 GlaxoSmithKline Plc. Latest Developments
13.6 Mallinckrodt Pharmaceuticals Plc.
13.6.1 Mallinckrodt Pharmaceuticals Plc. Company Information
13.6.2 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
13.6.3 Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Mallinckrodt Pharmaceuticals Plc. Main Business Overview
13.6.5 Mallinckrodt Pharmaceuticals Plc. Latest Developments
13.7 Cheisi Farmaceutici S.p.A
13.7.1 Cheisi Farmaceutici S.p.A Company Information
13.7.2 Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolios and Specifications
13.7.3 Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Cheisi Farmaceutici S.p.A Main Business Overview
13.7.5 Cheisi Farmaceutici S.p.A Latest Developments
13.8 Zambon Company S.p.A
13.8.1 Zambon Company S.p.A Company Information
13.8.2 Zambon Company S.p.A Pulmonary Drugs Product Portfolios and Specifications
13.8.3 Zambon Company S.p.A Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Zambon Company S.p.A Main Business Overview
13.8.5 Zambon Company S.p.A Latest Developments
13.9 Alaxia SAS
13.9.1 Alaxia SAS Company Information
13.9.2 Alaxia SAS Pulmonary Drugs Product Portfolios and Specifications
13.9.3 Alaxia SAS Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Alaxia SAS Main Business Overview
13.9.5 Alaxia SAS Latest Developments
13.10 Merck Sharp & Dohme Limited
13.10.1 Merck Sharp & Dohme Limited Company Information
13.10.2 Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolios and Specifications
13.10.3 Merck Sharp & Dohme Limited Pulmonary Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Merck Sharp & Dohme Limited Main Business Overview
13.10.5 Merck Sharp & Dohme Limited Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Pulmonary Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Pulmonary Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Inhaled Corticosteroids
Table 4. Major Players of Long Acting Beta-2 Agonists
Table 5. Major Players of Antihistamines
Table 6. Major Players of Vasodilators
Table 7. Major Players of Others
Table 8. Global Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 9. Global Pulmonary Drugs Sales Market Share by Type (2018-2023)
Table 10. Global Pulmonary Drugs Revenue by Type (2018-2023) & ($ million)
Table 11. Global Pulmonary Drugs Revenue Market Share by Type (2018-2023)
Table 12. Global Pulmonary Drugs Sale Price by Type (2018-2023) & (USD/Unit)
Table 13. Global Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 14. Global Pulmonary Drugs Sales Market Share by Application (2018-2023)
Table 15. Global Pulmonary Drugs Revenue by Application (2018-2023)
Table 16. Global Pulmonary Drugs Revenue Market Share by Application (2018-2023)
Table 17. Global Pulmonary Drugs Sale Price by Application (2018-2023) & (USD/Unit)
Table 18. Global Pulmonary Drugs Sales by Company (2018-2023) & (K Units)
Table 19. Global Pulmonary Drugs Sales Market Share by Company (2018-2023)
Table 20. Global Pulmonary Drugs Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Pulmonary Drugs Revenue Market Share by Company (2018-2023)
Table 22. Global Pulmonary Drugs Sale Price by Company (2018-2023) & (USD/Unit)
Table 23. Key Manufacturers Pulmonary Drugs Producing Area Distribution and Sales Area
Table 24. Players Pulmonary Drugs Products Offered
Table 25. Pulmonary Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Pulmonary Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Pulmonary Drugs Sales Market Share Geographic Region (2018-2023)
Table 30. Global Pulmonary Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Pulmonary Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Pulmonary Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Pulmonary Drugs Sales Market Share by Country/Region (2018-2023)
Table 34. Global Pulmonary Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Pulmonary Drugs Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Pulmonary Drugs Sales by Country (2018-2023) & (K Units)
Table 37. Americas Pulmonary Drugs Sales Market Share by Country (2018-2023)
Table 38. Americas Pulmonary Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Pulmonary Drugs Revenue Market Share by Country (2018-2023)
Table 40. Americas Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 41. Americas Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 42. APAC Pulmonary Drugs Sales by Region (2018-2023) & (K Units)
Table 43. APAC Pulmonary Drugs Sales Market Share by Region (2018-2023)
Table 44. APAC Pulmonary Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Pulmonary Drugs Revenue Market Share by Region (2018-2023)
Table 46. APAC Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 47. APAC Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 48. Europe Pulmonary Drugs Sales by Country (2018-2023) & (K Units)
Table 49. Europe Pulmonary Drugs Sales Market Share by Country (2018-2023)
Table 50. Europe Pulmonary Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Pulmonary Drugs Revenue Market Share by Country (2018-2023)
Table 52. Europe Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 53. Europe Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Pulmonary Drugs Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Pulmonary Drugs Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Pulmonary Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Pulmonary Drugs Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Pulmonary Drugs
Table 61. Key Market Challenges & Risks of Pulmonary Drugs
Table 62. Key Industry Trends of Pulmonary Drugs
Table 63. Pulmonary Drugs Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Pulmonary Drugs Distributors List
Table 66. Pulmonary Drugs Customer List
Table 67. Global Pulmonary Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Pulmonary Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Pulmonary Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Pulmonary Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Pulmonary Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Pulmonary Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Pulmonary Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Pulmonary Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Pulmonary Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Pulmonary Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Pulmonary Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Pulmonary Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Pulmonary Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Pulmonary Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Sanofi SA Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Sanofi SA Pulmonary Drugs Product Portfolios and Specifications
Table 83. Sanofi SA Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. Sanofi SA Main Business
Table 85. Sanofi SA Latest Developments
Table 86. Meda Pharmaceuticals Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Meda Pharmaceuticals Pulmonary Drugs Product Portfolios and Specifications
Table 88. Meda Pharmaceuticals Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. Meda Pharmaceuticals Main Business
Table 90. Meda Pharmaceuticals Latest Developments
Table 91. Circassia Pharmaceuticals Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 93. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. Circassia Pharmaceuticals Plc. Main Business
Table 95. Circassia Pharmaceuticals Plc. Latest Developments
Table 96. AstraZeneca Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. AstraZeneca Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 98. AstraZeneca Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. AstraZeneca Plc. Main Business
Table 100. AstraZeneca Plc. Latest Developments
Table 101. GlaxoSmithKline Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 103. GlaxoSmithKline Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. GlaxoSmithKline Plc. Main Business
Table 105. GlaxoSmithKline Plc. Latest Developments
Table 106. Mallinckrodt Pharmaceuticals Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 108. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. Mallinckrodt Pharmaceuticals Plc. Main Business
Table 110. Mallinckrodt Pharmaceuticals Plc. Latest Developments
Table 111. Cheisi Farmaceutici S.p.A Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolios and Specifications
Table 113. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 114. Cheisi Farmaceutici S.p.A Main Business
Table 115. Cheisi Farmaceutici S.p.A Latest Developments
Table 116. Zambon Company S.p.A Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Zambon Company S.p.A Pulmonary Drugs Product Portfolios and Specifications
Table 118. Zambon Company S.p.A Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 119. Zambon Company S.p.A Main Business
Table 120. Zambon Company S.p.A Latest Developments
Table 121. Alaxia SAS Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Alaxia SAS Pulmonary Drugs Product Portfolios and Specifications
Table 123. Alaxia SAS Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 124. Alaxia SAS Main Business
Table 125. Alaxia SAS Latest Developments
Table 126. Merck Sharp & Dohme Limited Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolios and Specifications
Table 128. Merck Sharp & Dohme Limited Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 129. Merck Sharp & Dohme Limited Main Business
Table 130. Merck Sharp & Dohme Limited Latest Developments
Table 1. Pulmonary Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Pulmonary Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Inhaled Corticosteroids
Table 4. Major Players of Long Acting Beta-2 Agonists
Table 5. Major Players of Antihistamines
Table 6. Major Players of Vasodilators
Table 7. Major Players of Others
Table 8. Global Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 9. Global Pulmonary Drugs Sales Market Share by Type (2018-2023)
Table 10. Global Pulmonary Drugs Revenue by Type (2018-2023) & ($ million)
Table 11. Global Pulmonary Drugs Revenue Market Share by Type (2018-2023)
Table 12. Global Pulmonary Drugs Sale Price by Type (2018-2023) & (USD/Unit)
Table 13. Global Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 14. Global Pulmonary Drugs Sales Market Share by Application (2018-2023)
Table 15. Global Pulmonary Drugs Revenue by Application (2018-2023)
Table 16. Global Pulmonary Drugs Revenue Market Share by Application (2018-2023)
Table 17. Global Pulmonary Drugs Sale Price by Application (2018-2023) & (USD/Unit)
Table 18. Global Pulmonary Drugs Sales by Company (2018-2023) & (K Units)
Table 19. Global Pulmonary Drugs Sales Market Share by Company (2018-2023)
Table 20. Global Pulmonary Drugs Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Pulmonary Drugs Revenue Market Share by Company (2018-2023)
Table 22. Global Pulmonary Drugs Sale Price by Company (2018-2023) & (USD/Unit)
Table 23. Key Manufacturers Pulmonary Drugs Producing Area Distribution and Sales Area
Table 24. Players Pulmonary Drugs Products Offered
Table 25. Pulmonary Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Pulmonary Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Pulmonary Drugs Sales Market Share Geographic Region (2018-2023)
Table 30. Global Pulmonary Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Pulmonary Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Pulmonary Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Pulmonary Drugs Sales Market Share by Country/Region (2018-2023)
Table 34. Global Pulmonary Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Pulmonary Drugs Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Pulmonary Drugs Sales by Country (2018-2023) & (K Units)
Table 37. Americas Pulmonary Drugs Sales Market Share by Country (2018-2023)
Table 38. Americas Pulmonary Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Pulmonary Drugs Revenue Market Share by Country (2018-2023)
Table 40. Americas Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 41. Americas Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 42. APAC Pulmonary Drugs Sales by Region (2018-2023) & (K Units)
Table 43. APAC Pulmonary Drugs Sales Market Share by Region (2018-2023)
Table 44. APAC Pulmonary Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Pulmonary Drugs Revenue Market Share by Region (2018-2023)
Table 46. APAC Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 47. APAC Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 48. Europe Pulmonary Drugs Sales by Country (2018-2023) & (K Units)
Table 49. Europe Pulmonary Drugs Sales Market Share by Country (2018-2023)
Table 50. Europe Pulmonary Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Pulmonary Drugs Revenue Market Share by Country (2018-2023)
Table 52. Europe Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 53. Europe Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Pulmonary Drugs Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Pulmonary Drugs Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Pulmonary Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Pulmonary Drugs Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Pulmonary Drugs Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Pulmonary Drugs Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Pulmonary Drugs
Table 61. Key Market Challenges & Risks of Pulmonary Drugs
Table 62. Key Industry Trends of Pulmonary Drugs
Table 63. Pulmonary Drugs Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Pulmonary Drugs Distributors List
Table 66. Pulmonary Drugs Customer List
Table 67. Global Pulmonary Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Pulmonary Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Pulmonary Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Pulmonary Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Pulmonary Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Pulmonary Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Pulmonary Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Pulmonary Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Pulmonary Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Pulmonary Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Pulmonary Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Pulmonary Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Pulmonary Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Pulmonary Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Sanofi SA Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Sanofi SA Pulmonary Drugs Product Portfolios and Specifications
Table 83. Sanofi SA Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 84. Sanofi SA Main Business
Table 85. Sanofi SA Latest Developments
Table 86. Meda Pharmaceuticals Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Meda Pharmaceuticals Pulmonary Drugs Product Portfolios and Specifications
Table 88. Meda Pharmaceuticals Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 89. Meda Pharmaceuticals Main Business
Table 90. Meda Pharmaceuticals Latest Developments
Table 91. Circassia Pharmaceuticals Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Circassia Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 93. Circassia Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 94. Circassia Pharmaceuticals Plc. Main Business
Table 95. Circassia Pharmaceuticals Plc. Latest Developments
Table 96. AstraZeneca Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. AstraZeneca Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 98. AstraZeneca Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 99. AstraZeneca Plc. Main Business
Table 100. AstraZeneca Plc. Latest Developments
Table 101. GlaxoSmithKline Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. GlaxoSmithKline Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 103. GlaxoSmithKline Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 104. GlaxoSmithKline Plc. Main Business
Table 105. GlaxoSmithKline Plc. Latest Developments
Table 106. Mallinckrodt Pharmaceuticals Plc. Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Product Portfolios and Specifications
Table 108. Mallinckrodt Pharmaceuticals Plc. Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 109. Mallinckrodt Pharmaceuticals Plc. Main Business
Table 110. Mallinckrodt Pharmaceuticals Plc. Latest Developments
Table 111. Cheisi Farmaceutici S.p.A Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 112. Cheisi Farmaceutici S.p.A Pulmonary Drugs Product Portfolios and Specifications
Table 113. Cheisi Farmaceutici S.p.A Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 114. Cheisi Farmaceutici S.p.A Main Business
Table 115. Cheisi Farmaceutici S.p.A Latest Developments
Table 116. Zambon Company S.p.A Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Zambon Company S.p.A Pulmonary Drugs Product Portfolios and Specifications
Table 118. Zambon Company S.p.A Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 119. Zambon Company S.p.A Main Business
Table 120. Zambon Company S.p.A Latest Developments
Table 121. Alaxia SAS Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Alaxia SAS Pulmonary Drugs Product Portfolios and Specifications
Table 123. Alaxia SAS Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 124. Alaxia SAS Main Business
Table 125. Alaxia SAS Latest Developments
Table 126. Merck Sharp & Dohme Limited Basic Information, Pulmonary Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Merck Sharp & Dohme Limited Pulmonary Drugs Product Portfolios and Specifications
Table 128. Merck Sharp & Dohme Limited Pulmonary Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 129. Merck Sharp & Dohme Limited Main Business
Table 130. Merck Sharp & Dohme Limited Latest Developments
LIST OF FIGURES
Figure 1. Picture of Pulmonary Drugs
Figure 2. Pulmonary Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pulmonary Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Pulmonary Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Pulmonary Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Inhaled Corticosteroids
Figure 10. Product Picture of Long Acting Beta-2 Agonists
Figure 11. Product Picture of Antihistamines
Figure 12. Product Picture of Vasodilators
Figure 13. Product Picture of Others
Figure 14. Global Pulmonary Drugs Sales Market Share by Type in 2022
Figure 15. Global Pulmonary Drugs Revenue Market Share by Type (2018-2023)
Figure 16. Pulmonary Drugs Consumed in Asthma & COPD
Figure 17. Global Pulmonary Drugs Market: Asthma & COPD (2018-2023) & (K Units)
Figure 18. Pulmonary Drugs Consumed in Allergic Rhinitis
Figure 19. Global Pulmonary Drugs Market: Allergic Rhinitis (2018-2023) & (K Units)
Figure 20. Pulmonary Drugs Consumed in Pulmonary Arterial Hypertension
Figure 21. Global Pulmonary Drugs Market: Pulmonary Arterial Hypertension (2018-2023) & (K Units)
Figure 22. Pulmonary Drugs Consumed in Cystic Fibrosis
Figure 23. Global Pulmonary Drugs Market: Cystic Fibrosis (2018-2023) & (K Units)
Figure 24. Pulmonary Drugs Consumed in Others
Figure 25. Global Pulmonary Drugs Market: Others (2018-2023) & (K Units)
Figure 26. Global Pulmonary Drugs Sales Market Share by Application (2022)
Figure 27. Global Pulmonary Drugs Revenue Market Share by Application in 2022
Figure 28. Pulmonary Drugs Sales Market by Company in 2022 (K Units)
Figure 29. Global Pulmonary Drugs Sales Market Share by Company in 2022
Figure 30. Pulmonary Drugs Revenue Market by Company in 2022 ($ Million)
Figure 31. Global Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 32. Global Pulmonary Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 33. Global Pulmonary Drugs Revenue Market Share by Geographic Region in 2022
Figure 34. Americas Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 35. Americas Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 36. APAC Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 37. APAC Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 38. Europe Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 39. Europe Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 40. Middle East & Africa Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 41. Middle East & Africa Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 42. Americas Pulmonary Drugs Sales Market Share by Country in 2022
Figure 43. Americas Pulmonary Drugs Revenue Market Share by Country in 2022
Figure 44. Americas Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 45. Americas Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 46. United States Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. Canada Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 48. Mexico Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. Brazil Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. APAC Pulmonary Drugs Sales Market Share by Region in 2022
Figure 51. APAC Pulmonary Drugs Revenue Market Share by Regions in 2022
Figure 52. APAC Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 53. APAC Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 54. China Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Japan Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. South Korea Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. Southeast Asia Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. India Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 59. Australia Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. China Taiwan Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. Europe Pulmonary Drugs Sales Market Share by Country in 2022
Figure 62. Europe Pulmonary Drugs Revenue Market Share by Country in 2022
Figure 63. Europe Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 64. Europe Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 65. Germany Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. France Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. UK Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 68. Italy Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. Russia Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Middle East & Africa Pulmonary Drugs Sales Market Share by Country in 2022
Figure 71. Middle East & Africa Pulmonary Drugs Revenue Market Share by Country in 2022
Figure 72. Middle East & Africa Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 73. Middle East & Africa Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 74. Egypt Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. South Africa Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 76. Israel Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 77. Turkey Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 78. GCC Country Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 79. Manufacturing Cost Structure Analysis of Pulmonary Drugs in 2022
Figure 80. Manufacturing Process Analysis of Pulmonary Drugs
Figure 81. Industry Chain Structure of Pulmonary Drugs
Figure 82. Channels of Distribution
Figure 83. Global Pulmonary Drugs Sales Market Forecast by Region (2024-2029)
Figure 84. Global Pulmonary Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 85. Global Pulmonary Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 86. Global Pulmonary Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 87. Global Pulmonary Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 88. Global Pulmonary Drugs Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Pulmonary Drugs
Figure 2. Pulmonary Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Pulmonary Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Pulmonary Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Pulmonary Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Inhaled Corticosteroids
Figure 10. Product Picture of Long Acting Beta-2 Agonists
Figure 11. Product Picture of Antihistamines
Figure 12. Product Picture of Vasodilators
Figure 13. Product Picture of Others
Figure 14. Global Pulmonary Drugs Sales Market Share by Type in 2022
Figure 15. Global Pulmonary Drugs Revenue Market Share by Type (2018-2023)
Figure 16. Pulmonary Drugs Consumed in Asthma & COPD
Figure 17. Global Pulmonary Drugs Market: Asthma & COPD (2018-2023) & (K Units)
Figure 18. Pulmonary Drugs Consumed in Allergic Rhinitis
Figure 19. Global Pulmonary Drugs Market: Allergic Rhinitis (2018-2023) & (K Units)
Figure 20. Pulmonary Drugs Consumed in Pulmonary Arterial Hypertension
Figure 21. Global Pulmonary Drugs Market: Pulmonary Arterial Hypertension (2018-2023) & (K Units)
Figure 22. Pulmonary Drugs Consumed in Cystic Fibrosis
Figure 23. Global Pulmonary Drugs Market: Cystic Fibrosis (2018-2023) & (K Units)
Figure 24. Pulmonary Drugs Consumed in Others
Figure 25. Global Pulmonary Drugs Market: Others (2018-2023) & (K Units)
Figure 26. Global Pulmonary Drugs Sales Market Share by Application (2022)
Figure 27. Global Pulmonary Drugs Revenue Market Share by Application in 2022
Figure 28. Pulmonary Drugs Sales Market by Company in 2022 (K Units)
Figure 29. Global Pulmonary Drugs Sales Market Share by Company in 2022
Figure 30. Pulmonary Drugs Revenue Market by Company in 2022 ($ Million)
Figure 31. Global Pulmonary Drugs Revenue Market Share by Company in 2022
Figure 32. Global Pulmonary Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 33. Global Pulmonary Drugs Revenue Market Share by Geographic Region in 2022
Figure 34. Americas Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 35. Americas Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 36. APAC Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 37. APAC Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 38. Europe Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 39. Europe Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 40. Middle East & Africa Pulmonary Drugs Sales 2018-2023 (K Units)
Figure 41. Middle East & Africa Pulmonary Drugs Revenue 2018-2023 ($ Millions)
Figure 42. Americas Pulmonary Drugs Sales Market Share by Country in 2022
Figure 43. Americas Pulmonary Drugs Revenue Market Share by Country in 2022
Figure 44. Americas Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 45. Americas Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 46. United States Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. Canada Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 48. Mexico Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 49. Brazil Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 50. APAC Pulmonary Drugs Sales Market Share by Region in 2022
Figure 51. APAC Pulmonary Drugs Revenue Market Share by Regions in 2022
Figure 52. APAC Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 53. APAC Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 54. China Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. Japan Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. South Korea Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. Southeast Asia Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. India Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 59. Australia Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 60. China Taiwan Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 61. Europe Pulmonary Drugs Sales Market Share by Country in 2022
Figure 62. Europe Pulmonary Drugs Revenue Market Share by Country in 2022
Figure 63. Europe Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 64. Europe Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 65. Germany Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. France Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. UK Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 68. Italy Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 69. Russia Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 70. Middle East & Africa Pulmonary Drugs Sales Market Share by Country in 2022
Figure 71. Middle East & Africa Pulmonary Drugs Revenue Market Share by Country in 2022
Figure 72. Middle East & Africa Pulmonary Drugs Sales Market Share by Type (2018-2023)
Figure 73. Middle East & Africa Pulmonary Drugs Sales Market Share by Application (2018-2023)
Figure 74. Egypt Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. South Africa Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 76. Israel Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 77. Turkey Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 78. GCC Country Pulmonary Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 79. Manufacturing Cost Structure Analysis of Pulmonary Drugs in 2022
Figure 80. Manufacturing Process Analysis of Pulmonary Drugs
Figure 81. Industry Chain Structure of Pulmonary Drugs
Figure 82. Channels of Distribution
Figure 83. Global Pulmonary Drugs Sales Market Forecast by Region (2024-2029)
Figure 84. Global Pulmonary Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 85. Global Pulmonary Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 86. Global Pulmonary Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 87. Global Pulmonary Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 88. Global Pulmonary Drugs Revenue Market Share Forecast by Application (2024-2029)
